WVE
HealthcareWave Life Sciences Ltd.
$15.00
$-0.95 (-5.96%)
Jan 5, 2026
Price History (1Y)
Analysis
Wave Life Sciences Ltd. is a biotechnology company within the healthcare sector. Its market capitalization is $2.79 billion, indicating a significant scale of operations. The company employs 287 individuals and generated revenue of $109.23 million in its most recent trailing twelve months. From a financial perspective, Wave Life Sciences exhibits substantial losses. Its profit margins are deeply negative, with gross margin at -59.9%, operating margin at -740.7%, and profit margin at -111.6%. The company's net income is -$121,946,000 over the same period, accompanied by negative EBITDA of $-132,446,000 and free cash flow of $-147,693,120. In contrast to its significant losses, Wave Life Sciences has a relatively strong balance sheet with $196.22 million in cash and only $19.77 million in debt. Wave Life Sciences' valuation metrics include a forward P/E ratio of -12.38, indicating that investors are anticipating substantial future improvements in earnings. The company's price to book is 19.31 and price to sales is 25.51. Its beta is -1.82, suggesting a high level of volatility relative to the market.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Visit website →Key Statistics
- Market Cap
- $2.79B
- P/E Ratio
- N/A
- 52-Week High
- $21.73
- 52-Week Low
- $5.28
- Avg Volume
- 6.50M
- Beta
- -1.82
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- Singapore
- Employees
- 287